Novartis Ag Company Profile

Aggregated data from the web about Novartis Ag

Company Name	Novartis Ag
Website	https://www.novartis.com
Snippet	Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma. October 26, 2021. Media Release. Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz.
ISIN	CH0012005267
Type	Public (Aktiengesellschaft)
Founded	1996, (from merger)
Revenue	US$49.89 billion (2020)[2]
Website	Novartis.com
Founders	Johann RudolfAlexander Clavel
Industry	Pharmaceuticals
Products	Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health (list...)
Traded as	SIX: NOVN, NYSE: NVS
Key people	Vasant Narasimhan (CEO)[1]
Net income	US$8.07 billion (2020)[2]
Area served	Worldwide
Predecessor	Ciba-Geigy, Sandoz (via merger)
Headquarters	Basel, Switzerland
Total assets	US$132.06 billion (2020)[2]
Total equity	US$56.67 billion (2020)[2]
Operating income	US$10.15 billion (2020)[2]
Number of employees	110,000 (2020)[2]

Novartis Ag is part of the Switzerland company list

Novartis Ag is part of the Pharmaceuticals company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.